Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 14/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CALML3 | P27482 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2848391 | 1.00 | GRM2 (0.47) | GRM2MAOBCALML3S1PR5 | |
| SCHEMBL3198798 | 0.90 | GRM2 (0.49) | GRM2MAOBCALML3S1PR5 | |
| SCHEMBL9611100 | 0.86 | GRM2 (0.49) | GRM2CALML3S1PR5 | |
| SCHEMBL8991499 | 0.85 | POLB (0.47) | GRM2 | |
| SCHEMBL17769268 | 0.85 | GRM2 (0.47) | GRM2MAOBCALML3S1PR5 | |
| SCHEMBL17769267 | 0.85 | GRM2 (0.47) | GRM2MAOBCALML3S1PR5 | |
| SCHEMBL17769259 | 0.84 | GRM2 (0.47) | GRM2CALML3S1PR5 | |
| SCHEMBL17769261 | 0.84 | GRM2 (0.47) | GRM2CALML3S1PR5 | |
| SCHEMBL541807 | 0.84 | CALML3 (0.59) | GRM2MAOBCALML3S1PR5 | |
| SCHEMBL7545023 | 0.84 | GRM2 (0.60) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2256120-A1 | Oxazolidinone-quinolone hybrids as antibacterial compounds | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-20100222302-A1 | Novel Antibacterial Compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222302-A1 | Novel Antibacterial Compounds | ODC1, AOC1, OGFOD1 | GRM2 2313/4885MAOB 1605/4885CALML3 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.